Sorrento Therapeutics Concludes Enrollment In Abivertinib Mid-Stage COVID-19 Trials In US, Brazil

  • Sorrento Therapeutics Inc SRNE has completed enrollment for its Phase 2 trial of Abivertinib in hospitalized COVID-19 patients in Brazil. 
  • This study completion follows the recently completed enrollment of the U.S. Phase 2 clinical trial.
  • In two to three months, the company expects to be able to disclose top-line data. 
  • Price Action: SRNE shares are down 1.73% at $8.54 during the market trading session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCovid-19Phase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!